The 20-gene test helps measure the “stemness” of tumours to indicate the likelihood of cancer progression. Credit: swiftsciencewriting from Pixabay.

AccuStem Sciences and EmeritusDX have signed an agreement to jointly manage the research and development (R&D) and scientific operations for the formers’ product portfolio.

Under the collaboration, the companies will initially focus on further validating AccuStem’s StemPrintER test for breast cancer patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

StemPrintER is a 20-gene test that stratifies patients as per its recurrence risk and is mainly used for measuring the “stemness” of tumours to indicate the likelihood of cancer progression and response to standard treatment modalities.

The alliance aims to further establish the assay’s utility in tackling unresolved clinical questions, including the identification of surgical interventions that can enhance outcomes.

Furthermore, the partnership aims to offer healthcare providers actionable insights for improved patient outcomes in the fight against cancer by empowering them with the tools to make informed decisions.

See Also:

AccuStem CEO Wendy Blosser said: “Their expertise in the diagnostic space in combination with their proven track record of success is exactly what AccuStem has been looking for in a lab partner to take StemPrintER through the validation and reimbursement process for breast cancer and other indications.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

EmeritusDX has modern facilities in Pennsylvania and California in the US and the company will leverage its molecular laboratories and a seasoned R&D team for validating the StemPrintER assay.

EmeritusDX CEO Robert Embree said: “AccuStem’s proprietary technology evaluating tumour stemness offers endless opportunities for healthcare providers to address a variety of clinically unmet needs for cancer patients.

“StemPrintER complements our existing product pipeline by addressing additional questions along the patient care continuum beyond what we are currently doing today.”